Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer

Proteomics

Volumn 8, Issue 15, 2008, Pages 3051-3060

  Grote, Tobias ^a   Siwak, Doris R ^a   Fritsche, Herbert A ^a   Joy, Corwin ^a   Mills, Gordon B ^a   Simeone, Diane ^b   Whitcomb, David C ^c   Logsdon, Craig D ^a,d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Biomarker; CA19 9; Pancreatic cancer; Reverse phase protein array

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CA 19-9 ANTIGEN;

ANTIGEN DETECTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC PANCREATITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; REVERSE PHASE PROTEIN ARRAY; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

BIOLOGICAL MARKERS; BLOOD PROTEINS; CA-19-9 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PANCREATIC NEOPLASMS; PLASMA; PROTEIN ARRAY ANALYSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SERUM;

EID: 49749088333     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.200700951     Document Type: Article

References (30)

1. Anderson, N. L., Anderson, N. G., The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
2. Etzioni, R., Urban, N., Ramsey, S., McIntosh, M. et al., The case for early detection. Nat. Rev. Cancer 2003, 3, 243-252.
3. Grote, T., Logsdon, C. D., Progress on molecular markers of pancreatic cancer. Curr. Opin. Gastroenterol. 2007, 23, 508-514.
4. Ward, J. B., Jr., Henderson, R. E., Identification of needs in biomarker research. Environ. Health Perspect. 1996, 104, 895-900.
5. Jemal, A., Siegel, R., Ward, E., Murray, T. et al., Cancer statistics 2007. CA Cancer J. Clin. 2007, 57, 43-66.
6. Boeck, S., Stieber, P., Holdenrieder, S., Wilkowski, R., Heinemann, V., Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006, 70, 255-264.
7. Locker, G. Y., Hamilton, S., Harris, J., Jessup, J. M. et al., ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 2006, 24, 5313-5327.
8. Iacobuzio-Donahue, C. A., Ashfaq, R., Maitra, A., Adsay, N. V. et al., Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 2003, 63, 8614-8622.
9. Logsdon, C. D., Simeone, D. M., Binkley, C., Arumugam, T. et al., Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63, 2649-2657.
10. Missiaglia, E., Blaveri, E., Terris, B., Wang, Y. H. et al., Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int. J. Cancer 2004, 112, 100-112.
11. Lin, Y., Goedegebuure, P. S., Tan, M. C., Gross, J. et al., Proteins associated with disease and clinical course in pancreas cancer: A proteomic analysis of plasma in surgical patients. J. Proteome Res. 2006, 5, 2169-2176.
12. Sun, Z. L., Zhu, Y., Wang, F. Q., Chen, R. et al., Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim. Biophys. Acta 2007, 1774, 764-771.
13. Simeone, D. M., Ji, B., Banerjee, M., Arumugam, T. et al., CEACAM1, a novel serum biomarker for pancreatic cancer. Pancreas 2007, 34, 436-443.
14. Hu, J., He, X., Baggerly, K. A., Coombes, K. R. et al., Non-parametric quantification of protein lysate arrays. Bioinformatics 2007, 23, 1986-1994.
15. Tibes, R., Qiu, Y., Lu, Y., Hennessy, B. et al., RP protein array: Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2006, 5, 2512-2521.
16. Grubb, R. L., Calvert, V. S., Wulkuhle, J. D., Paweletz, C. P. et al., Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003, 3, 2142-2146.
17. Petricoin, E. F., III, Espina, V., Araujo, R. P., Midura, B. et al., Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007, 67, 3431-3440.
18. Koopmann, J., Zhang, Z., White, N., Rosenzweig, J. et al., Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 2004, 10, 860-868.
19. Furukawa, T., Duguid, W. P., Rosenberg, L., Viallet, J. et al., Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 1996, 148, 1763-1770.
20. Peiper, M., Nagoshi, M., Patel, D., Fletcher, J. A. et al., Human pancreatic cancer cells (MPanc-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int. J. Cancer 1997, 71, 993-999.
21. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L. et al., Reverse phase protein microarrays which capture disease progression show activation of prosurvival pathways at the cancer invasion front. Oncogene 2001, 20, 1981-1989.
22. Geho, D., Lahar, N., Gurnani, P., Huebschman, M. et al., Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. Bioconjug. Chem. 2005, 16, 559-566.
23. Shingyoji, M. G. D., Pinkel, D., Gray, J. W., Chen, F., Quantum dots-based reverse phase protein microarray. Talanta 2005, 67, 472-478.
24. Nishizuka, S., Charboneau, L., Young, L., Major, S. et al., Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 2003, 100, 14229-14234.
25. Hamelinck, D., Zhou, H., Li, L., Verweij, C. et al., Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol. Cell. Proteomics 2005, 4, 773-784.
26. Janzi, M., Odling, J., Pan-Hammarstrom, Q., Sundberg, M. et al., Serum microarrays for large scale screening of protein levels. Mol. Cell. Proteomics 2005, 4, 1942-1947.
27. Orchekowski, R., Hamelinck, D., Li, L., Gliwa, E. et al., Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005, 65, 11193-11202.
28. Liew, M., Groll, M. C., Thompson, J. E., Call, S. L. et al., Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples. Biotechniques 2007, 42, 327-323.
29. Patwa, T. H., Zhao, J., Anderson, M. A., Simeone, D. M., Lubman, D. M., Screening of glycosylation patterns in serum using natural glycoprotein microarrays and multi-lectin fluorescence detection. Anal. Chem. 2006, 78, 6411-6421.
30. Zhao, J., Patwa, T. H., Qiu, W., Shedden, K. et al., Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J. Proteome Res. 2007, 6, 1864-1874.